Furthermore, we demonstrated for the first time, using an experimental setting that closely mimics in vivo conditions and an HO-1 inhibitor already in clinical use, that inhibition of HO-1 might enhance the efficacy of Vemurafenib/PLX4032 as a therapeutic in the treatment of melanoma. The gene discussed is HMOX1; the disease is melanoma.